Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Acetaminophen (APAP)‐induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver‐type fatty acid binding protein (FABP1) early (day 1) or late (day 3‐5) levels are associated with 21‐day mortality in the absence of liver transplant. Serum samples from 198 APAP‐ALF patients (nested case–control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme‐linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998‐2014). APAP‐ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P = 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21‐day mortality after adjusting for significant covariates (Model for End‐Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all). Conclusion: In patients with APAP‐ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP‐ALF warrants further investigation. (H epatology 2017;65:938‐949)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Early indicators of prognosis in fulminant hepatic failure
O'Grady, J. G., Alexander, G. J. M., Hayllar, K. M., & Williams, R. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90081-4 · Cited by 2,085
Cited by
Drug-induced liver injury: a comprehensive review
Hosack, T., Damry, D., & Biswas, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231163410 · Cited by 214
Management of Acute Liver Failure: Update 2022
Tujios, S., Stravitz, R. T., & Lee, W. M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755274 · Cited by 117
Self-citationLow Serum Hepcidin Is Associated With Reduced Short‐Term Survival in Adults With Acute Liver Failure
Spivak, I., Arora, J., Meinzer, C., Durkalski‐Mauldin, V., Lee, W. M., Trautwein, C., Fontana, R. J., & Strnad, P. (2019) · Hepatology · doi:10.1002/hep.30486 · Cited by 32
Self-citationShahbaz, O., Mahajan, S., & Lewis, J. H. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1362391 · Cited by 30
Unraveling the effect of intra- and intercellular processes on acetaminophen-induced liver injury
Heldring, M. M., Shaw, A. H., & Beltman, J. B. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00238-5 · Cited by 23
Metadata
- Authors
- Karvellas, C. J., Speiser, J. L., Tremblay, M., Lee, W. M., Rose, C. F., & for the US Acute Liver Failure Study Group
- Venue
- Hepatology
- Published
- 2017-01-19
- Volume
- 65
- Issue
- 3
- Pages
- 938-949
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2549803295
- Cited by
- 71
- References
- 2
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.